{
    "organizations": [],
    "uuid": "ba75548f3640e5326c31c27fab3d42f434df8028",
    "author": "",
    "url": "https://www.reuters.com/article/brief-puma-biotechnology-and-medison-pha/brief-puma-biotechnology-and-medison-pharma-enter-licensing-agreement-to-commercialize-nerlynx-in-israel-idUSFWN1PP0U2",
    "ord_in_thread": 0,
    "title": "BRIEF-Puma Biotechnology And Medison Pharma Enter Licensing Agreement To Commercialize Nerlynx In Israel",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 30, 2018 / 1:29 PM / in 13 minutes BRIEF-Puma Biotechnology And Medison Pharma Enter Licensing Agreement To Commercialize Nerlynx In Israel Reuters Staff 1 Min Read \nJan 30 (Reuters) - Puma Biotechnology Inc: \n* PUMA BIOTECHNOLOGY AND MEDISON PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNXÂ® (NERATINIB) IN ISRAEL \n* PUMA BIOTECHNOLOGY INC - CO, MEDISON PHARMA LTD ENTERED INTO EXCLUSIVE AGREEMENT UNDER WHICH MEDISON WILL COMMERCIALIZE NERLYNX IN ISRAEL \n* PUMA BIOTECHNOLOGY SAYS WILL RECEIVE UPFRONT, MILESTONE PAYMENTS THROUGHOUT AGREEMENT TERM, & DOUBLE DIGIT ROYALTIES ON NERLYNX SALES IN ISRAEL \n* PUMA BIOTECHNOLOGY SAYS EXPECT TO RECEIVE REGULATORY APPROVAL FOR NERLYNX IN ISRAEL DURING H1 2019 Source text for Eikon: Further company coverage:",
    "published": "2018-01-30T15:29:00.000+02:00",
    "crawled": "2018-01-30T15:50:20.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "minute",
        "biotechnology",
        "medison",
        "pharma",
        "enter",
        "licensing",
        "agreement",
        "commercialize",
        "nerlynx",
        "israel",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "puma",
        "biotechnology",
        "inc",
        "puma",
        "biotechnology",
        "medison",
        "pharma",
        "enter",
        "exclusive",
        "licensing",
        "agreement",
        "commercialize",
        "neratinib",
        "israel",
        "puma",
        "biotechnology",
        "inc",
        "co",
        "medison",
        "pharma",
        "ltd",
        "entered",
        "exclusive",
        "agreement",
        "medison",
        "commercialize",
        "nerlynx",
        "israel",
        "puma",
        "biotechnology",
        "say",
        "receive",
        "upfront",
        "milestone",
        "payment",
        "throughout",
        "agreement",
        "term",
        "double",
        "digit",
        "royalty",
        "nerlynx",
        "sale",
        "israel",
        "puma",
        "biotechnology",
        "say",
        "expect",
        "receive",
        "regulatory",
        "approval",
        "nerlynx",
        "israel",
        "h1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}